Business
Availability of Transgene’s 2025 Universal Registration Document (URD)
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2025 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 9, 2026, under number D.26-0241. This document, available on the AMF’s website (www.amf-france.org), can be viewed and downloaded (in PDF format in French and English, and in ESEF forma
About this update from Transgene Sa
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2025 Universal Registration Document was filed with the French Financial Markets Authority ( Autorité des marchés financiers – AMF) on April 9, 2026, under number D.26-0241. This document, available on the AMF’s website ( www.amf-france.org ), can be viewed and downloaded (in PDF format in French and English, and in ESEF format in French only) on Transgene’s website ( www.transgene.com ). It includes the following documents: The Universal Registration Document also includes information on the Company’s Environmental, Social and Governance (ESG) factors. Attachment